Bruker’s (BRKR) Buy Rating Reiterated at Guggenheim

Guggenheim restated their buy rating on shares of Bruker (NASDAQ:BRKR) in a report released on Monday morning,Benzinga reports.

BRKR has been the topic of several other research reports. Wells Fargo & Company lowered their target price on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th. UBS Group started coverage on shares of Bruker in a research note on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 price objective on the stock. Bank of America raised their target price on shares of Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. Stifel Nicolaus decreased their target price on shares of Bruker from $70.00 to $57.00 and set a “hold” rating on the stock in a research note on Friday, February 14th. Finally, TD Cowen cut their price objective on shares of Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a report on Wednesday, November 6th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Bruker presently has a consensus rating of “Moderate Buy” and a consensus price target of $70.50.

Bruker Trading Down 1.0 %

Shares of BRKR opened at $50.49 on Monday. The firm has a 50 day moving average price of $56.39 and a 200-day moving average price of $59.81. Bruker has a fifty-two week low of $48.07 and a fifty-two week high of $94.86. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. The firm has a market cap of $7.65 billion, a price-to-earnings ratio of 66.43, a PEG ratio of 2.16 and a beta of 1.16.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. As a group, equities research analysts forecast that Bruker will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Monday, March 17th will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date is Monday, March 17th. Bruker’s payout ratio is 26.32%.

Institutional Trading of Bruker

A number of hedge funds and other institutional investors have recently modified their holdings of BRKR. Wealth Enhancement Advisory Services LLC lifted its stake in Bruker by 1.4% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 13,287 shares of the medical research company’s stock valued at $779,000 after buying an additional 177 shares during the last quarter. Quadrant Capital Group LLC lifted its position in shares of Bruker by 18.2% in the fourth quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company’s stock valued at $75,000 after acquiring an additional 196 shares in the last quarter. Insigneo Advisory Services LLC lifted its position in Bruker by 4.7% during the fourth quarter. Insigneo Advisory Services LLC now owns 4,880 shares of the medical research company’s stock worth $286,000 after buying an additional 218 shares during the period. Arizona State Retirement System lifted its position in Bruker by 0.7% during the fourth quarter. Arizona State Retirement System now owns 30,725 shares of the medical research company’s stock worth $1,801,000 after buying an additional 222 shares during the period. Finally, CIBC Asset Management Inc increased its stake in Bruker by 5.6% during the fourth quarter. CIBC Asset Management Inc now owns 4,233 shares of the medical research company’s stock worth $248,000 after acquiring an additional 223 shares during the last quarter. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.